Revolution Medicines, Inc. (RVMD) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped RVMD stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Revolution Medicines appears to be in a strong position within the biotech sector, supported by a promising product pipeline, consensus bullish views, and positive clinical trial outcomes. While there are risks from competition, high cash burn, and equity issuance, the long-term growth story justifies a bullish stance. The saved 1-year distribution is P10 $125, P50 $175, and P90 $210.
Last analyzed · Model: gpt-4o
Revolution Medicines, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $125 | Pessimistic plausible scenario |
| P50 | $175 | Median scenario |
| P90 | $210 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
The company's recent progress in clinical trials and expansion in the oncology market is promising. Analysts are overwhelmingly positive about its short-term prospects, reflected by a strong buy consensus. However, negative signals from recent equity issuance and increased competition reduce the bullishness slightly.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this RVMD analysis generated?
June 11, 2026.
Is this a guaranteed RVMD prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full RVMD stock analysis · RVMD sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.